APC anti-mouse IL-2 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

E. coli-expressed, recombinant mouse IL-2

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Red Laser (633 nm)

Application Notes

ELISA Detection^1-3 or ELISPOT Detection^4-6: The biotinylated JES6-5H4 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with the purified JES6-1A12 antibody (Cat. Nos. 503701 & 503702) as capture antibody and recombinant mouse IL-2 (Cat. No. 575409) as the standard.
Flow Cytometry^8-10: The fluorochrome-labeled JES6-5H4 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-2 -producing cells within mixed cell populations.
Neutralization^1,7: The Ultra-LEAF™ purified antibody (Endotoxin in vivo and in vitro (Cat. No. 503845-503850)) is recommended for neutralization.
Additional reported applications (for the relevant formats) include: immunoprecipitation¹, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections², in vivo capture⁷, and immunocytochemistry.
Note: For testing mouse IL-2 in serum, plasma or supernatant, BioLegend's ELISA MAX™ Sets (Cat. No. 431001 & 431004) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)

1. Abrams J, et al. 1992. Immunol. Rev. 127:5.
2. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
3. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20.
4. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19.
5. Mo X, et al. 1995. J. Virol. 69:1288.
6. Karulin A, et al. 2000. J. Immunol. 164:1862.
7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
8. Ko SY, et al. 2005. J. Immunol. 175:3309. PubMed
9. Kang SS and Allen PM. 2005. J. Immunol. 174:5382.
10. Lawson BR, et al. 2007. J. Immunol. 178:5366.

Product Citations

1. Caslin HL, et al. 2023. Front Immunol. 13:984859. PubMed
2. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
3. Read KA, et al. 2023. Nat Commun. 14:1652. PubMed
4. Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed
5. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
6. Maschmeyer P, et al. 2017. J Autoimmun.. 10.1016/j.jaut.2017.11.005. PubMed
7. Ma Z, et al. 2014. PLoS One. 9:112292. PubMed
8. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
9. Marangoni F, et al. 2021. Cell. . PubMed
10. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
11. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
12. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
13. Hanna CC, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
14. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
15. Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed
16. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
17. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
18. Souza SP, et al. 2021. PLoS Pathog. 17:e1010081. PubMed
19. Pandit M, et al. 2021. Eur J Immunol. 51:1461. PubMed
20. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
21. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
22. Truckenbrod EN, et al. 2021. Elife. 10:. PubMed
23. Shimba A et al. 2018. Immunity. 48(2):286-298 . PubMed
24. Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed
25. Lei F, et al. 2012. J Vis Exp. 63: 3986. PubMed
26. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed

RRID

AB_315303 (BioLegend Cat. No. 503809)
AB_315303 (BioLegend Cat. No. 503810)

Antigen Details

Structure

Cytokine; 15-30 kD (Mammalian)

Bioactivity

Proliferation of T lymphocytes, B cells, anti-inflammatory, hematopoiesis, tumor surveillance

Cell Sources

T cells

Cell Targets

T cells, B cells, NK cells, LAK cells, monocytes, macrophages, oligodendrocytes

Receptors

High affinity heterotrimer of IL-2Rα/β/γ, intermediate affinity homodimer IL-2Rα (CD25; p55; Tac) and heterodimer IL-2Rβ (CD122)/γ; γ-subunit (CD132) in common with IL-4R, IL-7R, IL-13R, IL-15R

Cell Type

Tregs

Biology Area

Immunology

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Taniguchi T, et al. 1993. Cell 73:5.
3. Nistico G. 1993. Prog. Neurobiol. 40:463.
4. Waldmann T, et al. 1993. Ann. NY Acad. Sci. 685:603.

Regulation

Upregulated by NFAT; downregulated by TCF-8, CIF (colostrum inhibitory factor)

Gene ID

16183 View all products for this Gene ID

UniProt

View information about IL-2 on UniProt.org

Related Protocols

• Surface and Intracellular Cytokine Staining for Flow Cytometry - Video
• Intracellular Flow Cytometry Staining Protocol

Other Formats